147 related articles for article (PubMed ID: 36215173)
1. Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.
Bergamaschi L; Chiaravalli S; Livellara V; Sironi G; Puma N; Nigro O; Gattuso G; Luksch R; Terenziani M; Spreafico F; Meazza C; Podda M; Biassoni V; Schiavello E; Hovsepyan S; Morosi C; Vennarini S; Massimino M; Casanova M; Ferrari A
Pediatr Blood Cancer; 2023 Jan; 70(1):e30050. PubMed ID: 36215173
[TBL] [Abstract][Full Text] [Related]
2. Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse.
Chiaravalli S; Bergamaschi L; Livellara V; Sironi G; Puma N; Nigro O; Gattuso G; Luksch R; Terenziani M; Spreafico F; Meazza C; Podda M; Biassoni V; Schiavello E; Morosi C; Massimino M; Casanova M; Ferrari A
Eur J Cancer; 2022 Jul; 169():179-187. PubMed ID: 35576803
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
4. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.
Dantonello TM; Int-Veen C; Winkler P; Leuschner I; Schuck A; Schmidt BF; Lochbuehler H; Kirsch S; Hallmen E; Veit-Friedrich I; Bielack SS; Niggli F; Kazanowska B; Ladenstein R; Wiebe T; Klingebiel T; Treuner J; Koscielniak E
J Clin Oncol; 2008 Jan; 26(3):406-13. PubMed ID: 18202417
[TBL] [Abstract][Full Text] [Related]
5. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
6. Treatment at relapse for synovial sarcoma of children and adolescents: A multi-institutional European retrospective analysis.
Ferrari A; Orbach D; Bergamaschi L; Schoot RA; van Noesel MM; Di Carlo D; Bisogno G; Alaggio R; Milano GM; Chiaravalli S; Fuccillo F; Laurence V; Corradini N; Gasparini P; Vennarini S; Pasquali S; Casanova M
Pediatr Blood Cancer; 2024 Jul; 71(7):e31038. PubMed ID: 38679840
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience.
Park M; Lee JA; Jin HY; Kim JY; Park JW; Kim JH; Kang HG; Park SY; Park EY; Park HJ; Park BK
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3109-3119. PubMed ID: 35870013
[TBL] [Abstract][Full Text] [Related]
8. Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered.
Welmant J; Helfre S; Carton M; Bolle S; Minard-Colin V; Corradini N; Pannier S; Rome A; Mansuy L; Vérité C; Castex MP; Kerr C; Defachelles AS; Bernier V; Orbach D
Strahlenther Onkol; 2021 Aug; 197(8):690-699. PubMed ID: 33914102
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma.
Mazzoleni S; Bisogno G; Garaventa A; Cecchetto G; Ferrari A; Sotti G; Donfrancesco A; Madon E; Casula L; Carli M;
Cancer; 2005 Jul; 104(1):183-90. PubMed ID: 15895378
[TBL] [Abstract][Full Text] [Related]
10. Durability of oncological outcomes of combination chemotherapy as a monotherapy for a select patient subset with non-metastatic non-alveolar bladder/prostate rhabdomyosarcoma.
Abdelhalim A; Atwa AM; Helmy TE; Dawaba ME; Elashry R; Hafez AT
J Pediatr Urol; 2021 Aug; 17(4):535.e1-535.e8. PubMed ID: 34092511
[TBL] [Abstract][Full Text] [Related]
11. Local treatment in initially unresected non-rhabdomyosarcoma soft-tissue sarcomas of children and adolescents: A retrospective single-center experience.
Ferrari A; Vennarini S; Fiore M; Bergamaschi L; Chiaravalli S; Morosi C; Colombo C; Pecori E; Puma N; Luksch R; Terenziani M; Spreafico F; Meazza C; Podda M; Biassoni V; Schiavello E; Massimino M; Casanova M
Pediatr Blood Cancer; 2024 Apr; 71(4):e30901. PubMed ID: 38296840
[TBL] [Abstract][Full Text] [Related]
12. High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen.
Vijayasekharan K; Ramanathan S; Chinnaswamy G; Prasad M; Gulia A; Janu A; Rekhi B; Ramadwar M; Khanna N; Laskar S; Puranadare N; Bajpai J; Puri A; Banavali S; Vora T
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):185-192. PubMed ID: 32706630
[No Abstract] [Full Text] [Related]
13. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.
Ferrari A; De Salvo GL; Dall'Igna P; Meazza C; De Leonardis F; Manzitti C; De Ioris MA; Casanova M; Carli M; Bisogno G
Eur J Cancer; 2012 Dec; 48(18):3448-55. PubMed ID: 22835783
[TBL] [Abstract][Full Text] [Related]
14. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies.
Rogers T; Zanetti I; Coppadoro B; Martelli H; Jenney M; Minard-Colin V; Terwisscha van Scheltinga SEJ; Skerritt C; Fajardo RD; Guérin F; Kelsey A; Merks JHM; Mandeville H; Guillén G; Glosli H; De Corti F; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29739. PubMed ID: 35460336
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
Heinz AT; Ebinger M; Schönstein A; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter MW; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Rößler J; Ljungman G; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2023 Jul; 70(7):e30363. PubMed ID: 37066598
[TBL] [Abstract][Full Text] [Related]
16. Defining the impact of prognostic factors at the time of relapse for nonmetastatic rhabdomyosarcoma.
Affinita MC; Ferrari A; Chiaravalli S; Melchionda F; Quaglietta L; Casanova M; Zanetti I; Scarzello G; Di Pasquale L; Di Cataldo A; Bisogno G
Pediatr Blood Cancer; 2020 Dec; 67(12):e28674. PubMed ID: 32860661
[TBL] [Abstract][Full Text] [Related]
17. Second-line therapy in young patients with relapsed or refractory orbital rhabdomyosarcoma.
Zloto O; Minard-Colin V; Boutroux H; Brisse HJ; Levy C; Kolb F; Bolle S; Carton M; Helfre S; Orbach D
Acta Ophthalmol; 2021 May; 99(3):334-341. PubMed ID: 32833335
[TBL] [Abstract][Full Text] [Related]
18. Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single-center experience.
Ferrari A; Bergamaschi L; Chiaravalli S; Livellara V; Sironi G; Nigro O; Puma N; Gattuso G; Morosi C; Gasparini P; Caccavo R; Pecori E; Alessandro O; Vennarini S; Gandola L; Massimino M; Casanova M
Pediatr Blood Cancer; 2022 Nov; 69(11):e29853. PubMed ID: 35731852
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological characteristics, treatment outcome and prognostic factors in adult rhabdomyosarcoma: a monocentric retrospective study.
Saadi M; Letaief F; Gabsi A; Mokrani A; Meddeb K; Mezlini A
Pan Afr Med J; 2022; 41():246. PubMed ID: 35734321
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
Abd El-Aal HH; Habib EE; Mishrif MM
J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
